INMED PHARMACEUTICALS INC. Unrealized Loss on Foreign Currency Derivatives, before Tax
INMED PHARMACEUTICALS INC. (INM) reported Unrealized Loss on Foreign Currency Derivatives, before Tax of $75.93 thousand for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-23.
Financial Statements › Notes
us-gaap:UnrealizedLossOnForeignCurrencyDerivativesBeforeTax · last filed 2025-09-23
- INMED PHARMACEUTICALS INC. unrealized loss on foreign currency derivatives, before tax for the quarter ending 2025-06-30 was $31.05K, a 221.63% increase year-over-year.
- INMED PHARMACEUTICALS INC. unrealized loss on foreign currency derivatives, before tax for the quarter ending 2025-03-31 was $24.54K, a 1406.26% increase year-over-year.
- INMED PHARMACEUTICALS INC. unrealized loss on foreign currency derivatives, before tax for the quarter ending 2024-12-31 was $15.07K.
- INMED PHARMACEUTICALS INC. unrealized loss on foreign currency derivatives, before tax for the quarter ending 2024-09-30 was $5.27K, a 161.15% increase year-over-year.
- INMED PHARMACEUTICALS INC. unrealized loss on foreign currency derivatives, before tax for fiscal 2025 was $75.93K, a 519.21% increase from fiscal 2024.
- INMED PHARMACEUTICALS INC. unrealized loss on foreign currency derivatives, before tax for fiscal 2024 was $12.26K, a 936.52% increase from fiscal 2023.
- INMED PHARMACEUTICALS INC. unrealized loss on foreign currency derivatives, before tax for fiscal 2023 was $1.18K, a 33.16% decline from fiscal 2022.
- INMED PHARMACEUTICALS INC. unrealized loss on foreign currency derivatives, before tax for fiscal 2022 was $1.77K.
| Period end | Unrealized Loss on Foreign Currency Derivatives, before Tax 3 month | Unrealized Loss on Foreign Currency Derivatives, before Tax 6 month | Unrealized Loss on Foreign Currency Derivatives, before Tax 9 month | Unrealized Loss on Foreign Currency Derivatives, before Tax 12 month |
|---|---|---|---|---|
| 2025-06-30 | $31.05K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $55.59K derived: sum of 2 quarters · filed 2025-09-23 | $70.66K derived: sum of 3 quarters · filed 2025-09-23 | $75.93K 10-K · filed 2025-09-23 |
| 2025-03-31 | $24.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $39.60K derived: sum of 2 quarters · filed 2025-05-12 | $44.88K 10-Q · filed 2025-05-12 | $54.53K derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-12-31 | $15.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $20.34K 10-Q · filed 2025-02-12 | $29.99K derived: sum of 3 quarters · filed 2025-09-23 | $31.62K derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-09-30 | $5.27K 10-Q · filed 2024-11-14 | $14.93K derived: sum of 2 quarters · filed 2025-09-23 | $16.55K derived: sum of 3 quarters · filed 2025-09-23 | $15.51K derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-06-30 | $9.65K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $11.28K derived: sum of 2 quarters · filed 2025-09-23 | $10.24K derived: sum of 3 quarters · filed 2025-09-23 | $12.26K 10-K · filed 2025-09-23 |
| 2024-03-31 | $1.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $589.00 derived: sum of 2 quarters · filed 2025-05-12 | $2.61K 10-Q · filed 2025-05-12 | |
| 2023-12-31 | -$1.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $978.00 10-Q · filed 2025-02-12 | ||
| 2023-09-30 | $2.02K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $1.18K 10-K · filed 2024-09-30 | |||
| 2022-12-31 | -$629.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $2.17K 10-Q · filed 2024-02-13 | ||
| 2022-09-30 | $2.80K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $1.77K 10-K · filed 2023-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |